These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 4040553)

  • 1. Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy: a randomized double-blind controlled clinical trial.
    D'Olimpio JT; Camacho F; Chandra P; Lesser M; Maldonado M; Wollner D; Wiernik PH
    J Clin Oncol; 1985 Aug; 3(8):1133-5. PubMed ID: 4040553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
    J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
    Kris MG; Gralla RJ; Tyson LB; Clark RA; Cirrincione C; Groshen S
    J Clin Oncol; 1989 Jan; 7(1):108-14. PubMed ID: 2642536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial.
    Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tamura T; Tominaga K; Sakurai M; Sano T; Taito H; Takahashi H
    Jpn J Clin Oncol; 1986 Sep; 16(3):279-87. PubMed ID: 3534348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy.
    Markman M; Sheidler V; Ettinger DS; Quaskey SA; Mellits ED
    N Engl J Med; 1984 Aug; 311(9):549-52. PubMed ID: 6379459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexamethasone vs. placebo for cisplatin-induced emesis. A randomized cross-over trial.
    Dana BW; Everts EC; Dickinson D
    Am J Clin Oncol; 1985 Oct; 8(5):426-8. PubMed ID: 4061377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentobarbital's effect in a combination antiemetic regimen for cisplatin induced nausea and vomiting.
    Wheelock JB
    J Miss State Med Assoc; 1989 Jan; 30(1):5-8. PubMed ID: 2647995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy.
    Cassileth PA; Lusk EJ; Torri S; DiNubile N; Gerson SL
    Arch Intern Med; 1983 Jul; 143(7):1347-9. PubMed ID: 6347109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide.
    Aapro MS; Plezia PM; Alberts DS; Graham V; Jones SE; Surwit EA; Moon TE
    J Clin Oncol; 1984 May; 2(5):466-71. PubMed ID: 6539363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study.
    Carr BI; Bertrand M; Browning S; Doroshow JH; Presant C; Pulone B; Hill LR
    J Clin Oncol; 1985 Aug; 3(8):1127-32. PubMed ID: 4040552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
    Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
    Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
    Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
    Gralla RJ; Navari RM; Hesketh PJ; Popovic W; Strupp J; Noy J; Einhorn L; Ettinger D; Bushnell W; Friedman C
    J Clin Oncol; 1998 Apr; 16(4):1568-73. PubMed ID: 9552067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
    Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
    Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
    Campos D; Pereira JR; Reinhardt RR; Carracedo C; Poli S; Vogel C; Martinez-Cedillo J; Erazo A; Wittreich J; Eriksson LO; Carides AD; Gertz BJ
    J Clin Oncol; 2001 Mar; 19(6):1759-67. PubMed ID: 11251007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.